Skip to Content

Carbolith (lithium carbonate)

Audience: Neuropsychiatric healthcare professionals and consumers

The FDA advised consumers about a Canadian recall of Carbolith (lithium carbonate) 150 mg capsules distributed in Canada by Valeant Canada Limited. Although Carbolith is not an FDA-approved product, FDA is investigating several Internet websites advertising Carbolith for sale to U.S. consumers. Carbolith 150 mg capsules are used in the treatment of manic-depressive illness. The company's recent testing led to the conclusion that the product may not deliver adequate amounts of the drug to ensure effective treatment. U.S. consumers who have taken it for the treatment of manic-depressive illness could experience adverse events associated with lowered blood lithium levels.

[December 8, 2004 - Talk Paper - FDA]

More News Resources

Subscribe to our Newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of in your inbox.